AlphaYou
Overview
8 funds hold it, insiders have been net selling, and 16 straight earnings beats.
Key stats
Sep 5- Open
- $28.58
- 52-wk high
- $29.21
- High
- $28.69
- 52-wk low
- $22.03
- Low
- $28.38
- Prev close
- $28.81
- Mkt cap
- $164.21B
- P/E
- 37.9x
- Volume
- 23.79M
- Fwd P/E
- 9.8x
- Beta
- 0.28
- Div yield
- 5.93%
- P/S
- 2.6x
- P/B
- 1.9x
- Profit margin
- +6.8%
- Op margin
- +27.9%
- ROE
- +5.0%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsSmart money
8 funds hold a position, insiders have been net selling, and 1 fin-fluencer is discussing it.
What funds are doing
Earnings
Earnings came in 13.2% above what analysts expected.
Earnings per share
$0.68 expected
Revenue
$14.39B expected
GAAP EPS was -$0.04 and adjusted EPS was $0.77. The adjusted figure is comparable to consensus.
FY2026 guidance
$60.50B to $62.50B
No comparable estimate
What the street expects next
EPS expected
$0.59 to $0.94
Revenue expected
16 analysts
Last 30 days
Analysts cutting estimates
Estimate drift
Change in 30 days
What the company said
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $16.65B | $17.56B | $14.45B | $15.03B |
| Cost of what it sold | $4.17B | $5.27B | $4.73B | $4.09B |
| Gross profit | $12.48B | $12.29B | $9.72B | $10.94B |
| What it spent | ||||
| Research and development | $3.94B | $3.42B | $2.63B | $2.81B |
| Sales and admin | $3.19B | $4.08B | $2.96B | $3.41B |
| Other operating costs | $1.81B | $1.10B | $100.0M | — |
| Total operating expenses | $8.93B | $8.60B | $5.69B | $6.24B |
| What was left | ||||
| Operating profit | $3.55B | $3.69B | $4.03B | $4.71B |
| Interest on debt | $652.0M | $711.0M | $668.0M | $667.0M |
| Profit before tax | $3.33B | -$1.64B | $3.17B | -$653.0M |
| Tax | -$216.0M | -$2.0M | $461.0M | -$407.0M |
| Net profit | $3.54B | -$1.65B | $2.69B | -$246.0M |
| EBITDA | $5.65B | $756.0M | $5.02B | $1.20B |
Technicals
Price structure
This stock is in a strong uptrend.
Trend
Strong uptrend
100 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage leans bullish
Tone of tracked coverage
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
Leans bullishSep 4Was JNJ Stock Rally Actually Its Own?
NeutralSep 4Trailing rivals, AbbVie scores win with dual-acting myeloma drug
NeutralSep 4AbbVie’s Humira Cash Cow Is Shrinking—Can Its Dividend Keep Growing?
NeutralSep 4Jupiter Topco LLC Acquires New Position in Advance Auto Parts, Inc. $AAP
NeutralSep 4Ionis Pharma's drug becomes first FDA-approved treatment for rare brain disorder
NeutralSep 3FDA Approves Pfizer-BioNTech XFG-Adapted COVID-19 Vaccine for 2026-27 Season
BullishSep 3BlossomHill Therapeutics (NASDAQ:BLSM) Shares Gap Up - Here's Why
NeutralSep 3
Macro
11 macro signals shaping PFE right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results